<DOC>
	<DOCNO>NCT02935192</DOCNO>
	<brief_summary>A Phase 3 , double-blind , randomize , placebo-controlled trial seasonal , trivalent , split , inactivated influenza vaccine produce Torlak .</brief_summary>
	<brief_title>Phase 3 Trial Serbian Seasonal Influenza Vaccine</brief_title>
	<detailed_description>This phase 3 , double-blind , randomize , placebo- control trial two group participant receive seasonal trivalent split , inactivated influenza vaccine ( A/H1N1 ; A/H3N2 B ) placebo ( phosphate buffer saline ) . A total 480 healthy male female adult 18 65 year age ; 320 participant randomized receive vaccine and160 receive placebo ( 2:1 ratio ) . At least 25 % participant ( N=120 ) &gt; /= 45 year age ( 80 vaccine 40 placebo recipient ) . Safety assess participant Day 91 . Immunogenicity assess serum sample obtain baseline 21 day vaccination subset least 100 individual randomize study vaccine 50 placebo recipient .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 65 year old date consent Literate ( self report ) willing consent Healthy medically stable Women childbearing potential : breastfeeding pregnant ; willing use effective contraception Day 22 Receipt influenza vaccine within past 10 month Known suspected congenital acquire immunodeficiency History GuillainBarre Hypersensitivity response previous vaccination Allergic vaccine component ( egg ; antibiotic ) Any condition , opinion Investigator , would increase health risk participant interfere evaluate study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>seasonal influenza</keyword>
	<keyword>vaccine</keyword>
</DOC>